jimmy Turano

On Small Cap Drug Makers and Volatility

On Oct 19 02:31 AM Justin M. Hall wrote:

> Jimmy Turano:
>
> MRNA appears to be an decent company. I followed the company more
> closely under its previous name, NSTK.
>
> As I recall, the company recently announced a collaboration, which
> is a plus. The company is working to develop RNA-based therapeutics.
> I prefer to invest in late-stage, optionable small cap drug makers
> and MRNA. Since most, if not all, of MRNA's drugs are in very early
> stages, the company is not on my radar.
>
> In this space, MRNA competes with Alnylam (seekingalpha.com/symbo...)
> and a few other companies working to develop RNA-based drugs which
> I cannot recall at this time.
>
> Notable: MRK acquired RNA Therapeutics (seekingalpha.com/symbo...)
> in the fall of 2006.
>
> I liked MRNA when it was very cheap earlier in the year. As for buying
> MRNA right now, I do not have a preference as the company is just
> not on my radar.
>
> From my view, SPPI, ARIA, and other select [late-stage] drug makers
> are more attractive right now.
>
> I hope this helps. Good luck!
>
> Justin
THANK YOU JUSTIN, FOR MY OPINION RIGHT NOW IS THAT THE STOCK PRICE WILL DEPRECIATE BY AT LEAST 25%
BETWEEN NOW, OCTOBER 19TH AND DECEMBER 31ST, 2009. IT IS VERY LOGICAL AND REALISTIC.

On Small Cap Drug Makers and Volatility

Justin Hall, your article is interesting & good reading.
If you ever have a brief few minutes, can you give your
prospective on MDRNA INC(MRNA). IT IS A SMALL CAP, NO SERIOUS REVENUE, PLENTY OF EXPENSES, BUT PLENTY OF IN VIVO NEWS. WITH $4 DOLLAR TARGET PRICES BY RESEARCH FIRMS, AND SINCE 'MRNA' IS AT $1.33 RIGHT NOW ON 10/17/09, DOESN'T IT POSE A BUYING OPPORTUNITY OR SHOULD INVESTORS WAIT UNTIL YEAR END WHEN IT MAY BE AROUND. $92 CENTS?
WHAT DO YOU THINK JUSTIN?
LETS HAVE IT STRAIGHT!

Q1 2009 Biotech Earnings Roundup: The Good, the Bad, and the Ugly

MARK CIFRA-Since you are so informative to many investors, and helpful, I see you left out one stock that needs to be addressed please.
It cerntainly should fit one of your scenario's above.
THE GOD, THE BAD OR THE UGLY
Please give your perspective
on MDRNA INC(MRNA)
APPRECIATED IN ADVANCE!

Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly

WHY DID YOU LEAVE 'MRNA' OUT OF YOUR ARTCLE? AFTER ALL, IT IS A NEW COMPANY, NEW CEO, MADE TWO PARTNERING DEALS WITHIN 60 DAYS THIS YEAR. SOLD OFF LONG ISLAND HEADQUARTERS TO 'PAR'. GOT UPFRONT MILESTONE PAYMENT THIS YEAR TOO.
I MEAN SHOW A LITTLE RESPECT FOR A COMPANY THAT JUST WENT FROM $.27 CENTS TO $.75 CENTS WITHIN SEVERAL WEEKS. SO THEY MAY REVERSE SPLIT THE STOCK TO COMPLY WITH DE-LISTING. SO THEY MAY HAVE A NEWS RELEASE ABOUT 'GOING LETTER' OF CONCER. SO THEY HAVE HARDLY ANY EARNINGS & NO IMPROVED EARNINGS IN SIGHT. SO THEY HAVE A HUGE BURN RATE. SO THEY HAVE HIGH DEBT.
SO THEIR SALES GROWTH IS TERRIBLE.
THEY DO HAVE POTENTIAL!
EVEN IF IT MAY TAKE 4-7 YEARS.
IT IS A POSSIBILITY.
THIS COMPANY SHOULD FIT YOU STORY SOMEWHERE ABOUT THE 'GOOD', 'THE BAD', 'THE UGLY' SOMEHOW.
I MEAN THEY STILL EXIST AND SURVIVED SO FAR, WHY IS 'MRNA' NEVER COVERED BY SEEKING ALPHA?
FORGET THEIR BALANCE SHEETS AND STATISTICS, LOOK AT WHO MANAGEMENT KNOWS AND WHAT THEY ARE ACCOMPLISHING.
THEY HAVE MORE GOOD NEWS ANNOUNCEMENTS THAN THE WHITE HOUSE PRESS CORE. GIVE A LOOK!
CHECK THEIR BACKGROUNDS OUT.
CURRENT SHAREHOLDER WANT TO KNOW IF STOCK PRICE WILL CONTINUE INCREASE AND OR IS THIS A VIABLE LONG TERM PLAY AFTER ALL.

A Biotech Bloom in July

FANTASTIC ARTICLE! Good job. Of course not all bloomed nicely. There are always some weeds and the SEC should be the ones who pull them out.
Example, 'MRNA'. There has been so much damage to investors to date, that management ought not to be able to continue to pay themselves & exist for another 5,10, or 20 years. A total injustice to all!